In conclusion, MDK has emerged as a pivotal driver of PCAND pathogenesis and may function as a blood-based biomarker for discriminating between PCAND and T2DM in populations with new-onset diabetes, thereby facilitating the advancement of early detection strategies for pancreatic cancer. The gene discussed is MDK; the disease is familial pancreatic carcinoma.